Is this Multiple Myeloma?
Release Date: February 18, 2014
Expiration Date: February 18, 2015
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
What is often referred to as multiple myeloma is actually a disease spectrum, spanning a continuum from monoclonal gammopathy of undetermined significance (MGUS) to smoldering (asymptomatic) myeloma, both asymptomatic plasma cell dyscrasias with a heterogeneous propensity to progress from one to the other and finally on to various cytogenetic entities referred to as active symptomatic myeloma. One of the most crucial first steps in establishing a care and management plan for multiple myeloma patients is the appropriate diagnosis of the patient since these entities are treated differently in today’s practice.
This activity is designed for physicians, physician assistants, and pharmacists who have an interest in enhancing their clinical skills in treating patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Summarize diagnostic criteria for plasma cell disorders
- Summarize current guidelines regarding when to begin treatment
Is This Multiple Myeloma? – Parameswaran Hari, MD
Instructions for Participation and Credit
This activity is eligible for credit through February 18, 2015. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Parameswaran Hari, MD
Professor of Medicine
Section Head - Hematological Malignancies and BMT
Division of Hematology Oncology
Medical College of Wisconsin
Dr. Parameswaran Hari received his medical degree at Central University of Pondicherry, India, and completed postgraduate training in internal medicine and hematology in the United Kingdom. In addition, Dr. Hari completed a residency in internal medicine at Jefferson Health, Lankenau Hospital in Philadelphia, as well as a fellowship in oncology at the Medical College of Wisconsin. He is professor, Department of Medicine, and director of the Blood and Marrow Transplant Program at the Medical College of Wisconsin.
Dr. Hari is board certified by the Royal College of Physicians (internal medicine), Royal College of Pathologists (clinical and laboratory hematology), and holds membership in the American Society of Hematology. He is also the scientific director of the plasma cell disorders and lymphoma working committees of the Center for International Blood and Marrow Transplant Research (CIBMTR). Dr. Hari’s primary interests are in allogeneic hematopoietic stem cell transplantation and plasma cell disorders, multiple myeloma, AL amyloidosis and other monoclonal gammopathies.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .5 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-14-386-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Parameswaran Hari has received honoraria related to formal advisory activities and consultant fees from Celgene Corporation and Onyx, as well as consultant fees from Millennium: The Takeda Oncology Company and Sanofi. He has received grant support related to research activities from Celgene, Millennium, and Onyx.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Hari has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Hari has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation.
©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.